Janux Therapeutics (JANX) Change in Account Payables (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Change in Account Payables data on file, last reported at -$1.6 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$1.6 million, up 1.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (up 148.64% YoY), and the FY2025 annual result was $977000.0, down 38.32% from the prior year.
• Change in Account Payables declined to -$1.6 million in Q1 2026 per JANX's latest filing, from $1.7 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $1.7 million in Q4 2025 and troughed at -$1.6 million in Q1 2025.
• A 5-year average of $54823.5 and a median of -$107000.0 in 2023 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 415.35% in 2024 and fell as far as 326.17% in 2024.
• A 5-year view of Change in Account Payables shows it stood at $223000.0 in 2022, then soared by 46.64% to $327000.0 in 2023, then jumped by 376.76% to $1.6 million in 2024, then gained by 7.06% to $1.7 million in 2025, then sank by 196.58% to -$1.6 million in 2026.
• Business Quant data shows JANX's Change in Account Payables at -$1.6 million in Q1 2026, $1.7 million in Q4 2025, and -$168000.0 in Q3 2025.